GlaxoSmithKline has started a late-stage clinical trial of a drug in patients with an inflammatory disease that affects the blood vessels.
British drug maker GlaxoSmithKline will acquire development partner Human Genome Sciences for $3.6 billion, GSK said Monday.
GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.
A decision by a Food and Drug Administration advisory committee could pave the way for...
The Food and Drug Administration has decided to expedite the review of an investigational drug...
A developer of a new drug for treating lupus has entered a supply agreement with...
An investigational drug for lupus that could become the first new treatment for the disease...
Human Genome Sciences has submitted an approval application for a treatment for lupus, development partner...